Jennifer Beardsall and others alleged the labels were misleading because the products had low concentrations of acemannan, an important therapeutic component. They also alleged the products didn’t provide the therapeutic effects one would expect from a product marketed as aloe vera gel.
But the plaintiffs presented no evidence that acemannan concentration itself is actually salient to consumers, the ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.